Immune activation and benefit from avelumab in EBV-positive gastric cancer

Journal of the National Cancer Institute

Volumn 110, Issue 3, 2018, Pages 316-320

  Panda, Anshuman ^a   Mehnert, Janice M ^b,c   Hirshfield, Kim M ^e   Riedlinger, Greg ^d   Damare, Sherri ^b   Saunders, Tracie ^f   Kane, Michael ^g   Sokol, Levi ^h   Stein, Mark N ⁱ   Poplin, Elizabeth ^j   Rodriguez Rodriguez, Lorna ^k   Silk, Ann W ^b,j   Aisner, Joseph ^b,j   Chan, Nancy ^j   Malhotra, Jyoti ^l   Frankel, Melissa ^j   Kaufman, Howard L ^l   Ali, Siraj ^b   Ross, Jeffrey S ^m,n   White, Eileen P ^b   Bhanot, Gyan ^a   Ganesan, Shridar ^b   more..

^a Tumor Microenvironment and Metastasis Program   (United States)

^b Division of Gynecologic Oncology   (United States)

^c Phase i and Developmental Therapeutics Program   (United States)

^d Division of Translational Pathology   (United States)

^e Office of Human Research Services   (United States)

^f Pharmacy Department   (United States)

^g Gynecologic Oncology   (United States)

^h Division of Surgical Oncology   (United States)

ⁱ RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^j Department of Physics and Astronomy ^*  (United States)

^k RUTGERS UNIVERSITY   (United States)

^l ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^m FOUNDATION MEDICINE   (United States)

ⁿ ALBANY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AVELUMAB; B7 ANTIGEN; CD86 ANTIGEN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; RAMUCIRUMAB; VIRUS RNA; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADJUVANT RADIOTHERAPY; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DENDRITIC CELL; DISTANT METASTASIS; DYSPHAGIA; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; FRAMESHIFT MUTATION; GASTROINTESTINAL ENDOSCOPY; GENOME ANALYSIS; HEMATEMESIS; HUMAN; IMMUNE-RELATED GENE; IMMUNOREACTIVITY; LOCAL METASTASIS; LYMPH NODE METASTASIS; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; MEDIASTINUM LYMPH NODE; MEMORY T LYMPHOCYTE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MISMATCH REPAIR; NEOADJUVANT CHEMOTHERAPY; NONHUMAN; PARAAORTIC LYMPH NODE; PRIMARY TUMOR; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RNA SEQUENCE; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH CANCER; TFH CELL; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; AGED; ANTAGONISTS AND INHIBITORS; COMPLICATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROGNOSIS; STOMACH TUMOR; VIROLOGY;

AGED; ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICROSATELLITE INSTABILITY; PROGNOSIS; STOMACH NEOPLASMS;

EID: 85044938357     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djx213     Document Type: Article

References (21)

1. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PDl1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, openlabel, phase 1b trial. Lancet Oncol. 2016;17(6):717-726.
2. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A singlearm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-1920.
3. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-2199.
4. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207-211.
5. Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res. 2016; 4(11):959-967.
6. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-128.
7. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatchrepair deficiency. N Engl J Med. 2015;372(26):2509-2520.
8. Mehnert JM, Panda A, Zhong H, et al. Immune activation and response to pembrolizumab in pole-mutant endometrial cancer. J Clin Invest. 2016;126(6): 2334-2340.
9. Grogg KL, Lohse CM, Pankratz VS, Halling KC, Smyrk TC. Lymphocyte-rich gastric cancer: Associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol. 2003;16(7):641-651.
10. Chiaravalli AM, Feltri M, Bertolini V, et al. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch. 2006;448(3):344-353.
11. Derks S, Liao X, Chiaravalli AM, et al. Abundant PD-l1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget. 2016;7(22):32925-32932.
12. Ma C, Patel K, Singhi AD, et al. Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability. Am J Surg Pathol. 2016;40(11):1496-1506.
13. Kawazoe A, Kuwata T, Kuboki Y, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20(3):407-415.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
15. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023-1031.
16. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202-209.
17. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12): 1219-1223.
18. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5): 453-457.
19. Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
20. Kwong YL, Chan TSY, Tan D, et al. Pd1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase. Blood. 2017;129(17):2437-2442.
21. Gutman DA, Cobb J, Somanna D, et al. Cancer digital slide archive: An informatics resource to support integrated in silico analysis of TCGA pathology data. J Am Med Inform Assoc. 2013;20(6):1091-1098.